Antipsychotics and hyperprolactinaemia: mechanisms, consequences and management

被引:62
作者
Holt, Richard I. G. [1 ]
Peveler, Robert C. [2 ]
机构
[1] Univ Southampton, Endocrinol & Metab Sub Div, Dev Origins Adult Hlth & Dis Div, Sch Med, Southampton SO16 6YD, Hants, England
[2] Univ Southampton, Clin Neurosci Div, Sch Med, Southampton SO16 6YD, Hants, England
关键词
ATYPICAL ANTIPSYCHOTICS; DOUBLE-BLIND; PROLACTIN ELEVATION; SCHIZOPHRENIC-PATIENTS; RISPERIDONE; RISK; OLANZAPINE; HALOPERIDOL; PREVALENCE; QUETIAPINE;
D O I
10.1111/j.1365-2265.2010.03814.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
P>Hyperprolactinaemia is a common side effect in people receiving antipsychotics. The propensity to cause hyperprolactinaemia differs markedly between antipsychotics as a result of differential dopamine D-2 receptor-binding affinity and ability to cross the blood-brain barrier. Sexual dysfunction is common and under-recognized in people with severe mental illness and is in part caused by hyperprolactinaemia. There are a number of long-term consequences of hyperprolactinaemia, including osteoporosis. Regular monitoring before and during treatment will help identify those developing antipsychotic-induced hyperprolactinaemia. The treatment includes dose reduction and change in antipsychotic. Where this is not possible because of the risk of relapse of the mental illness, sex steroid replacement may be helpful in improving symptoms secondary to hypogonadism and reducing the risk of osteoporosis. Tertiary prevention of complications should also be considered.
引用
收藏
页码:141 / 147
页数:7
相关论文
共 72 条
[1]   Sex- and age-specific incidence of fractures in mental illness: A historical, population-based cohort study [J].
Abel, Kathryn M. ;
Heatlie, Heath F. ;
Howard, Louise M. ;
Webb, Roger T. .
JOURNAL OF CLINICAL PSYCHIATRY, 2008, 69 (09) :1398-1403
[2]  
[Anonymous], 2009, Schizophrenia: Core interventions in the treatment and management of schizophrenia in adults in primary and secondary care
[3]   Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice [J].
Asa, SL ;
Kelly, MA ;
Grandy, DK ;
Low, MJ .
ENDOCRINOLOGY, 1999, 140 (11) :5348-5355
[4]   Risperidone, but not olanzapine, decreases bone mineral densitv in female premenopausal schizophrenia patients [J].
Becker, D ;
Liver, O ;
Mester, R ;
Rapoport, M ;
Weizman, A ;
Weiss, M .
JOURNAL OF CLINICAL PSYCHIATRY, 2003, 64 (07) :761-766
[5]  
BILLER BMK, 1991, OBSTET GYNECOL, V78, P996
[6]   Frequency of sexual dysfunction and other reproductive side-effects in patients with schizophrenia treated with risperidone, olanzapine, quetiapine, or haloperidol:: The results of the EIRE study [J].
Bobes, J ;
García-Portilla, MP ;
Rejas, J ;
Hernández, G ;
Garcia-Garcia, M ;
Rico-Villademoros, F ;
Porras, A .
JOURNAL OF SEX & MARITAL THERAPY, 2003, 29 (02) :125-147
[7]   ENDOCRINE EFFECTS OF DOMPERIDONE - A PERIPHERAL DOPAMINE BLOCKING-AGENT [J].
BROWN, GM ;
VERHAEGAN, H ;
GREIDANUS, TBV ;
BRUGMANS, J .
CLINICAL ENDOCRINOLOGY, 1981, 15 (03) :275-282
[8]   TOLERANCE TO THE PROLACTIN-ELEVATING EFFECT OF NEUROLEPTICS [J].
BROWN, WA ;
LAUGHREN, TP .
PSYCHIATRY RESEARCH, 1981, 5 (03) :317-322
[9]  
Bushe Chris, 2008, J Psychopharmacol, V22, P46, DOI 10.1177/0269881107088435
[10]   Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics [J].
Bushe, Chris ;
Shaw, Michael .
JOURNAL OF PSYCHOPHARMACOLOGY, 2007, 21 (07) :768-773